At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...

Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...

The Trump administration may also be more aggressive targeting specific sectors, such as pharmacy benefit managers. Although ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...